These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 17479503)

  • 1. When and how to use tipranavir and darunavir.
    Hoffman CJ; Gallant JE
    AIDS Read; 2007 Apr; 17(4):194-8, 201. PubMed ID: 17479503
    [No Abstract]   [Full Text] [Related]  

  • 2. Trial of tipranavir versus darunavir in treatment-experienced patients enrolling.
    AIDS Patient Care STDS; 2007 Aug; 21(8):6-3. PubMed ID: 17902242
    [No Abstract]   [Full Text] [Related]  

  • 3. A lame duck, a dark horse, and a goat.
    Huff B
    GMHC Treat Issues; 2005; 19(5-6):4-5. PubMed ID: 16193576
    [No Abstract]   [Full Text] [Related]  

  • 4. Virologic response to tipranavir-ritonavir or darunavir-ritonavir based regimens in antiretroviral therapy experienced HIV-1 patients: a meta-analysis and meta-regression of randomized controlled clinical trials.
    Berhan A; Berhan Y
    PLoS One; 2013; 8(4):e60814. PubMed ID: 23593314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA notifications. Tentative approval to Aptivus for combination ART.
    AIDS Alert; 2007 Dec; 22(12):144. PubMed ID: 18411486
    [No Abstract]   [Full Text] [Related]  

  • 6. [Desensitization to tipranavir caused by toxicodermia].
    Martínez Castro B; Ferrando Piqueres R; Martínez García M; Soler Company E
    Farm Hosp; 2009; 33(6):340-2. PubMed ID: 20038397
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-HIV agents. Unexpected results from a tipranavir study.
    TreatmentUpdate; 2004; 16(3):6-7. PubMed ID: 17216836
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA notifications. Accelerated approval of tipranavir.
    AIDS Alert; 2005 Nov; 20(11):131. PubMed ID: 16363051
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug resistance mutations in HIV-infected patients in the Spanish drug resistance database failing tipranavir and darunavir therapy.
    Poveda E; Anta L; Blanco JL; Casado JL; Gutiérrez F; García F; Gómez-Sirvent JL; Iribarren JA; Soriano V; de Mendoza C;
    Antimicrob Agents Chemother; 2010 Jul; 54(7):3018-20. PubMed ID: 20479204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful use of a tipranavir/ritonavir-based antiretroviral regimen following development of viral resistance to darunavir.
    Pierone G; Urban T; Martin A; Mieras J; Kantor C
    HIV Clin Trials; 2008; 9(2):140-1. PubMed ID: 18474499
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-HIV agents. Tipranavir in treatment-experienced PHAs.
    TreatmentUpdate; 2005; 17(1):4-5. PubMed ID: 17225315
    [No Abstract]   [Full Text] [Related]  

  • 12. Salvage therapy update.
    Emery C
    Surviv News (Atlanta Ga); 2005; 16(6):8. PubMed ID: 16388538
    [No Abstract]   [Full Text] [Related]  

  • 13. Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial.
    Goldwirt L; Braun J; de Castro N; Charreau I; Barrail-Tran A; Delaugerre C; Raffi F; Lascoux-Combe C; Aboulker JP; Taburet AM; Molina JM
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3613-5. PubMed ID: 21576452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA approval: tipranavir.
    Sax PE
    AIDS Clin Care; 2005 Aug; 17(8):78. PubMed ID: 16193574
    [No Abstract]   [Full Text] [Related]  

  • 15. Protease inhibitors: the current status.
    Dauer B
    J HIV Ther; 2005 Dec; 10(4):72-4. PubMed ID: 16519246
    [No Abstract]   [Full Text] [Related]  

  • 16. Tipranavir (Aptivus): approval cautiously recommended.
    James JS
    AIDS Treat News; 2005 May; (412):2-3. PubMed ID: 16047408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA approves tipranavir.
    IAPAC Mon; 2005 Jul; 11(7):190. PubMed ID: 16676422
    [No Abstract]   [Full Text] [Related]  

  • 18. [Tipranavir optimizes the effect of recent antiretroviral substances. Encouraging options in multiple resistance].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():71. PubMed ID: 19024922
    [No Abstract]   [Full Text] [Related]  

  • 19. Interaction between atazanavir and fosamprenavir in the treatment of HIV-infected patients.
    Khanlou H; Bhatti L; Farthing C
    J Acquir Immune Defic Syndr; 2006 Jan; 41(1):124-5. PubMed ID: 16340485
    [No Abstract]   [Full Text] [Related]  

  • 20. New protease inhibitors and non-nucleoside reverse transcriptase inhibitors.
    Lascar M; Cartledge JD
    J HIV Ther; 2008 Jun; 13(2):40-4. PubMed ID: 18953273
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.